Pramipexole

Pramipexole
Systematic (IUPAC) name
(S)-N6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
Identifiers
CAS number 104632-26-0
ATC code N04BC05
PubChem 59868
DrugBank APRD00156
Chemical data
Formula C10H17N3S 
Mol. mass 211.324 g/mol
Pharmacokinetic data
Bioavailability >90%
Protein binding 15%
Half life 8-12 hours
Excretion Urine (90%), Feces (2%)
Therapeutic considerations
Pregnancy cat. B3(AU) C(US)
Legal status ℞ Prescription only
Routes Oral
 Yes check.svgY(what is this?)  (verify)

Pramipexole (Mirapex, Mirapexin, Sifrol) is a non-ergoline dopamine agonist indicated for treating early-stage Parkinson's disease (PD) and restless legs syndrome (RLS).1 It is also sometimes used off-label as a treatment for cluster headache and to counteract the problems with sexual dysfunction experienced by some users of the selective serotonin reuptake inhibitor (SSRI) antidepressants.2 Pramipexole has shown robust effects on pilot studies in a placebo-controlled proof of concept study in bipolar disorder.3 It is also being investigated for the treatment of clinical depression and fibromyalgia.456

Contents

  • 1 Pharmacology
  • 2 Adverse effects
  • 3 See also
  • 4 References
  • 5 External links

Pharmacology

Pramipexole acts as a partial/full agonist at the following receptors:78

  • D2S receptor (Ki = 3.9 nM; IA = 130%)
  • D2L receptor (Ki = 2.2 nM; IA = 70%)
  • D3 receptor (Ki = 0.5 nM; IA = 70%)
  • D4 receptor (Ki = 5.1 nM; IA = 42%)

Pramipexole also possesses low/insignificant affinity (500-10,000 nM) for the 5-HT1A, 5-HT1B, 5-HT1D, and α2-adrenergic receptors.97 It has negligible affinity (>10,000 nM) for the D1, D5, 5-HT2, α1-adrenergic, β-adrenergic, H1, and mACh receptors.97 All sites assayed were done using human tissues.78

Parkinson's disease is a neurodegenerative disease affecting the substantia nigra, a component of the basal ganglia. The substantia nigra has a high quantity of dopaminergic neurons, which are nerve cells that release the neurotransmitter known as dopamine. When dopamine is released, it may activate dopamine receptors in the striatum, which is another component of the basal ganglia. When neurons of the substantia nigra deteriorate in Parkinson's disease, the striatum no longer properly receives dopamine signals. As a result, the basal ganglia can no longer regulate body movement effectively and motor function becomes impaired. By acting as an agonist for the D2, D3, and D4 dopamine receptors, pramipexole may directly stimulate the underfunctioning dopamine receptors in the striatum, thereby restoring the dopamine signals needed for proper functioning of the basal ganglia.

Adverse effects

Some of the more common side effects of pramipexole include:1011

  • Changes in appetite and weight
  • Dizziness, lightheadedness, or fainting, especially when standing up (orthostatic hypotension)
  • Drowsiness
  • Hallucinations (seeing, hearing, or feeling things that are not there)
  • Nausea
  • Insomnia
  • Twitching, twisting, or other unusual body movements
  • Unusual tiredness or weakness

Several unusual adverse effects of pramipexole (and related D3-preferring dopamine agonist medications such as ropinirole) may include compulsive gambling, hypersexuality, and overeating,12 even in patients without any prior history of these behaviours.13 Other compulsive behaviors, such as excessive shopping and even cross-dressing, have been reported.14 These side effects are thought to be linked to the D3 activity of pramipexole, as D3 receptors are heavily expressed in brain regions involved in mood, behavior, and reward.15

See also

  • Piribedil
  • Ropinirole
  • Rotigotine

References

  1. ^ National Prescribing Service (2009). "Pramipexole for Parkinson's Disease". Medicines Update. Available at http://www.nps.org.au/consumers/publications/medicine_update/issues/Pramipexole_for_Parkinsons_disease
  2. ^ DeBattista C, Solvason HB, Breen JA, Schatzberg AF. (2000). "Pramipexole augmentation of a selective serotonin reuptake inhibitor in the treatment of depression.". J Clin Psychopharmacol. 20 (2): 274–275. PMID 10770475. 
  3. ^ Biol Psychiatry. 2004 Jul 1;56(1):54-60. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study.Zarate CA Jr, Payne JL, Singh J, Quiroz JA, Luckenbaugh DA, Denicoff KD, Charney DS, Manji HK.PMID: 15219473
  4. ^ Lattanzi L, Dell'Osso L, Cassano P, Pini S, Rucci P, Houck PR, Gemignani A, Battistini G, Bassi A, Abelli M, Cassano GB. (2002). "Pramipexole in treatment-resistant depression: a 16-week naturalistic study.". Bipolar Disord. 4 (5): 307–314. PMID 12479663. 
  5. ^ Cassano P, Lattanzi L, Soldani F, Navari S, Battistini G, Gemignani A, Cassano GB. (2004). "Pramipexole in treatment-resistant depression: an extended follow-up.". Depress Anxiety. 20 (3): 131–138. PMID 15549689. 
  6. ^ Holman AJ, Myers RR. (2005). "A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications.". Arthritis Rheum. 52 (8): 2495–2505. PMID 16052595. 
  7. ^ a b c d Kvernmo T, Härtter S, Burger E (August 2006). "A review of the receptor-binding and pharmacokinetic properties of dopamine agonists". Clinical Therapeutics 28 (8): 1065–78. doi:10.1016/j.clinthera.2006.08.004. PMID 16982285. http://linkinghub.elsevier.com/retrieve/pii/S0149-2918(06)00184-6. 
  8. ^ a b Newman-Tancredi A, Cussac D, Audinot V, et al. (November 2002). "Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor". The Journal of Pharmacology and Experimental Therapeutics 303 (2): 805–14. doi:10.1124/jpet.102.039875. PMID 12388667. http://jpet.aspetjournals.org/cgi/pmidlookup?view=long&pmid=12388667. 
  9. ^ a b Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A (November 2002). "Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes". The Journal of Pharmacology and Experimental Therapeutics 303 (2): 791–804. doi:10.1124/jpet.102.039867. PMID 12388666. http://jpet.aspetjournals.org/cgi/pmidlookup?view=long&pmid=12388666. 
  10. ^ "MedlinePlus Drug Information: Pramipexole (Systemic)". United States National Library of Medicine. http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/203739.html. Retrieved 2006-09-27. 
  11. ^ "FDA Prescribing Information: Mirapex (pramipexole dihydrochloride)". Food and Drug Administration (United States). http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020667s014s017s018lbl.pdf. Retrieved 2008-12-31. 
  12. ^ Wolters ECh, van der Werf YD, van den Heuvel OA. Parkinson's disease-related disorders in the impulsive-compulsive spectrum. Journal of Neurology. 2008 Sep;255 Suppl 5:48-56. PMID 18787882
  13. ^ Bostwick JM, Hecksel KA, Stevens SR, Bower JH, Ahlskog JE. Frequency of new-onset pathologic compulsive gambling or hypersexuality after drug treatment of idiopathic Parkinson disease. Mayo Clinic Proceedings. 2009 Apr;84(4):310-6. PMID 19339647
  14. ^ USA Today, Not Your Ordinary Side Effects, May 23, 2006
  15. ^ Dodd ML, Klos KJ, Bower JH, Geda YE, Josephs KA, Ahlskog JE (September 2005). "Pathological gambling caused by drugs used to treat Parkinson disease". Arch. Neurol. 62 (9): 1377–81. doi:10.1001/archneur.62.9.noc50009. PMID 16009751. 

External links

  • Mirapex.com - Manufacturer's website


v • d • e
Antiparkinson Agents (N04)
Dopaminergics
DA Precursors/Prodrugs
Etilevodopa • Droxidopa • Levodopa • Melevodopa
DA Receptor Agonists
Aplindore • Apomorphine • Bromocriptine • Cabergoline • Dihydroergocryptine • Lisuride • Pardoprunox • Pergolide • Piribedil • Pramipexole • Ropinirole • Rotigotine
MAO-B Inhibitors
Ladostigil • Lazabemide • Mofegiline • Pargyline • Rasagiline • Selegiline
COMT Inhibitors
Entacapone • Tolcapone
AAAD Inhibitors
Benserazide • Carbidopa • Methyldopa
Anticholinergics
Benzatropine • Biperiden • Bornaprine • Chlorphenoxamine • Cyrimine • Dexetimide • Dimenhydrinate • Diphenhydramine • Etanautine • Etybenzatropine • Mazaticol • Metixene • Orphenadrine • Phenglutarimide • Piroheptine • Procyclidine • Profenamine • Trihexyphenidyl • Tropatepine
Others
Amantadine • Budipine • Memantine • Rimantadine
v • d • e
Urologicals (G04)
Acidifiers
Ammonium chloride · Calcium chloride
Urinary antispasmodics
(primarily antimuscarinics)
Darifenacin · Emepronium · Fesoterodine · Flavoxate · Imidafenacin · Meladrazine · Oxybutynin · Propiverine · Solifenacin · Terodiline · Tolterodine · Trospium
For erectile dysfunction
Prostaglandins (E)
Alprostadil
PDE5 inhibitors
Avanafil · Sildenafil · Tadalafil · Udenafil · Vardenafil
Alpha blockers
Moxisylyte · Phentolamine · Yohimbine
Dopamine D4 receptor agonists
ABT-670 · ABT-724
Others
Apomorphine · Papaverine
Other urologicals
Acetohydroxamic acid · Salicylhydroxamic acid · Collagen · Dapoxetine · Dimethyl sulfoxide · Magnesium hydroxide · Pentosan polysulfate · Phenazopyridine · Phenyl salicylate · Succinimide
For BPH
5α-reductase inhibitors
Dutasteride · Finasteride
Alpha blockers (α1)
Alfuzosin · Doxazosin · Silodosin · Tamsulosin · Terazosin
Herbals
Pygeum africanum · Serenoa repens

Interested?

This nomenclature contains pharmaceutical base products, as well as heavy and fine chemicals which are currently supplied by us. In case of interest, please apply for our special offer stating quantity, quality and packing, thus ensuring speedy compliance with your requirements.
We also invite your enquiries relating to chemicals, pharmaceuticals and other items not mentioned in our product list.

Name*

E-Mail*

Subject

Phone

Message*

Attachment (max. 3.000 KBytes)

Security code*
captcha  » 

Send me a copy of above message

* required fields

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article http://en.wikipedia.org/wiki/Pramipexole. Additionally, in some cases elements from this article might be licensed under a different license. Please refer to the original article to check the license status http://en.wikipedia.org/wiki/Pramipexole.